Skip to content
Biotechnology, Medical Health Aged Care

New Medicines Manufacturing Innovation Centre opens: Monash accelerates medical innovation and development of life-saving treatments

Monash University 2 mins read

New Medicines Manufacturing Innovation Centre opens: Monash accelerates medical innovation and development of life-saving treatments 

 

Victorian Deputy Premier and Minister for Medical Research the Hon Ben Carroll today officially opened the newly built Medicines Manufacturing Innovation Centre (MMIC) within the heart of the Monash Technology Precinct, Clayton. 

 

Funded through an $8.58 million investment from the Victorian Higher Education State Investment Fund and $4 million from Monash University, MMIC’s expansion to Clayton builds on the Centre’s work based at the Monash Institute of Pharmaceutical Sciences (MIPS) in Parkville to provide further opportunities for innovation across medicine formulation, resolving manufacturing process challenges and building supply of highly-skilled, industry ready candidates for the workforce. 

 

Minister Carroll also announced a grant awarded to MMIC by the Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre). The grant will fund the development of a potential new therapeutic agent for the treatment of respiratory infections and inflammation, with the aim to help safeguard the community against both existing and future viruses.

 

Director of MMIC, Professor Michelle McIntosh said the Centre’s expansion to Clayton will deliver far-reaching benefits to the Victorian community.

 

“This new facility represents a significant advancement in Victoria’s research commercialisation opportunities. Our team of dedicated pharmaceutical scientists are committed to driving forward the end-to-end development of a range of medicines using state-of-the-art technology, from laboratory-scale projects right through to local manufacture of medicines for clinical trials,” Professor McIntosh said.

 

“We’re also thrilled to have Cumming Global Centre’s Professor Sharon Lewin join us for the MMIC launch. Fostering collaboration between research institutes is central to MMICs mission, and we are excited to be working with Professor Lewin and her team to progress a new treatment for respiratory viruses and further strengthen Australia’s resilience to future health emergencies,” Professor McIntosh said. 

 

Inaugural Director of the Cumming Global Centre, Melbourne Laureate Professor Sharon Lewin congratulated Professor McIntosh on the grant and said she looks forward to seeing the project come to fruition.

 

“In a globally competitive process, Professor McIntosh’s exploration of an innovative delivery system to treat future respiratory viruses stood out for both scientific excellence and its alignment to the Centre’s mission to advance the science behind therapeutics for pathogens of pandemic potential,” Professor Lewin said. 

Monash University Vice-Chancellor and President Professor Sharon Pickering said the permanent MMIC facility is an important new addition to the Monash Technology Precinct – a world class hub of research, industry, innovation and talent that is part of Victoria’s largest employment precinct outside the Melbourne CBD.

“This new facility will further strengthen the research and development capability of the Monash Technology Precinct innovation ecosystem, joining world-leading research and technology organisations such the CSIRO, the Melbourne Centre for Nanofabrication, the Victorian Heart Hospital and the soon-to-be completed Moderna manufacturing facility.

 

“By being located in the world-class Monash Technology Precinct, the MMIC will provide our researchers, precinct partners and local and international companies the opportunity to develop, test and scale-up new medicines here in Australia without going off-shore.”

MMIC Clayton is a purpose designed and built facility including laboratory and office space, co-located with the Australian Synchrotron in the heart of the Monash Technology Precinct, promoting further economic opportunities and growing employment.

ENDS

 


Contact details:

Kate Carthew

0438 674 814

[email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 13/05/2026
  • 23:10
Wellgistics Health, Inc.

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030,…

  • Contains:
  • Medical Health Aged Care
  • 13/05/2026
  • 22:10
Sapu Bioscience, LLC

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle(TM) Formulation of Everolimus

First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCCSAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sapu Nano today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, the Company’s investigational intravenous Deciparticle™ formulation of everolimus.The trial: SP-03-B101 — Sapu003 in Patients with Advanced mTOR-sensitive Solid Tumors (NCT07369505), is a Phase 1b, open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The investigational product is administered…

  • Medical Health Aged Care
  • 13/05/2026
  • 17:33
Palliative Care Australia

Budget a welcome step towards fairer end-of-life care

Palliative Care Australia has welcomed Australian Government Budget announcements that will improve support for people receiving end-of-life care at home, while calling for further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.